● TIER 2 — Compoundable · emerging dataGRADE CHealing / repair
BPC-157
Synthetic gastric pentadecapeptide. Research verification: Yes (TGA pending). 2 human study record(s) in the FitClinicMD studies database.
GOALS · Recovery / injury
FDA status
Not approved.
Compounding (503A/503B)
Covered by HHS's interim enforcement-discretion policy for compounded peptides (filed Oct 28, 2026): FDA will exercise enforcement discretion for 503A compounding of BPC-157 that meets the policy's ~10 conditions, while 503A bulks-list rulemaking is still pending. This is enforcement discretion, NOT an FDA approval or a bulks-list listing — and the BPC-157 free base is excluded (only the covered salt form qualifies). FDA scientists had recommended against listing; the PCAC had voted in favor.
DEA
Not controlled.
WADA (sport)
S0 Non-approved substances
↻ Regulatory status updated 2026-11-13 for the HHS interim enforcement-discretion policy.
Mechanism
Proposed NO/VEGF/growth-factor effects; rodent data.
Human evidence · 2
Systematic review (HSS J 2025): human evidence limited to small, low-quality reports; preclinical dominance. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Narrative review 2025 on musculoskeletal healing and risks. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Reference only. This page summarizes publicly available regulatory and research information about BPC-157. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.
Related compounds
● TIER 3GRADE C
Actovegin (deproteinized calf-blood hemodialysate)
Origin: Austria/Russia (Takeda, later others); widely used in Russia/E.
● TIER 3GRADE C
Dalargin (Даларгин)
Synthetic Leu-enkephalin analog Tyr-D-Ala-Gly-Phe-Leu-Arg.
● TIER 3GRADE B
Heberprot-P (recombinant human EGF) — Cuba
Origin: Cuba (CIGB).